TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects up to 2 years of age~* Signed informed consent by subject's parent/legal guardian~* UCD diagnosis or suspected diagnosis of any subtype, except N-acetyl glutamate synthetase deficiency. If UCD has not been previously confirmed by genetic testing, consent must be obtained from parent/legal guardian prior to perform genetic testing. If genetic testing is inconsistent with or excludes a UCD diagnosis, the subject will be withdrawn from the study.~Exclusion Criteria:~* Use of any investigational drug within 30 days of Day 1~* Uncontrolled infection (viral or bacterial) or any other condition known to precipitate hyperammonemic crises. Once these precipitating factors are medically controlled, patients presenting in crisis are eligible.~* Any clinical or laboratory abnormality of Grade 3 or greater severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03, except Grade 3 elevations in ammonia and liver enzymes, defined as levels 5-20 times the upper limit of normal in alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyl transpeptidase (GGT) in a clinically stable subject~* Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the subject at increased risk by participating in this study~* Known hypersensitivity to phenylacetate (PAA) or phenylbutyrate (PBA)~* Liver transplantation, including hepatocellular transplant~* Subjects on hemodialysis at time of initiating RAVICTI~* Subjects on RAVICTI for UCD management~* Currently treated with Carbaglu® (carglumic acid)

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- RAVICTI (Type: EXPERIMENTAL): RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Histologically confirmed diagnosis of PTCL of the following subtypes: Nodal T-cell lymphoma with T-follicular helper (TFH) phenotype (tumor cells must express 2 or 3 TFH-related antigens, including PD1, CD10, BCL6, CXCL13, ICOS, SAP and CCR5)\* Angioimmunoblastic T-cell lymphoma Follicular T-cell lymphoma PTCL/NOS, T-follicular helper (TFH) variant PTCL-NOS Anaplastic large cell lymphoma, ALK negative Anaplastic large cell lymphoma, ALK positive with IPI \> 2 Adult T-cell leukemia / lymphoma~* No prior systemic therapy for lymphoma~* Measurable disease defined by a tumor mass ≥ 1.5 cm in one dimension and measurable in two dimensions~* ECOG performance status ≤ 2~Exclusion Criteria:~* Known central nervous system (CNS) involvement by lymphoma~* Active viral infection with HIV or hepatitis type B or C (seropositive HBV patients are eligible if they are negative for HBV DNA by PCR and receive concomitant antiviral therapy).~* Prior history of malignancies other than PTCL unless the patient has been disease free for ≥ 5 years from the signing of the ICF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CC486 +CHOP (Type: EXPERIMENTAL): CC486 +CHOP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Under clozapine with negative symptoms~Exclusion Criteria:~* Pregnancy~* Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Clozapine plus placebo
- 2 (Type: ACTIVE_COMPARATOR): Clozapine plus memantine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed type 2 diabetes defined as WHO (1999) diagnostic criteria ; Both Genders Eligible;~2. Men or women aged 20 to 75 years;~3. Stable dosage of oral anti-diabetic medicine ,stable glycemia control(HbA1c\<7.5%), unchanged antidiabetic therapy during the trial;~4. Hypertriglycerides (3.4mmol/L≤mean fasting blood triglycerides\<22.60mmol/L, and not receiving any lipid lowering therapy for 3 days continuously or accumulated 7 days within 6 weeks before screening).~Exclusion Criteria:~1. Uncontrolled blood pressure (defined as systolic blood pressure\>180mmHg or diastolic blood pressure\>100mmHg);~2. Other diseases affecting lipid and glucose metabolism: hyperthyroidism，cushing syndrome ect;~3. Receiving insulin treatment in 6 months before recruitment;~4. Diagnosed heart failure, defined as New York Heart Association class III or IV;~5. Histories of acute or chronic pancreatitis，or cholelithiasis （except those received cholecystectomy）~6. Significant impaired liver function (defined as alanine transaminase (ALT)\> 3 times upper limit of normal), or active liver disease;~7. PLT\<60×10\^9/L，Hb\<100g/L；~8. Impaired renal function (defined as serum creatinine\> 135 mmol/L（1.5 mg/dL, male) and \> 110 mmol/L （1.3 mg/dL,female）；~9. Recorded history of malignant tumor in the past 2 years;~10. Histories of acute cerebrovascular accident within 6 months;~11. Pregnancy;~12. Known history of allergy to fish, shellfish and omega-3 fatty acids, or ineffective treatment of omega-3 fatty acids;~13. Simultaneous participation in any other clinical trial of an active pharmacologic agent within 30 days;~14. Other situations that interfere with the subject's ability to comply with study instructions;~15. Any other condition that investigators believe would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A Drug (Type: EXPERIMENTAL): Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure
- Group B Drug (Type: PLACEBO_COMPARATOR): Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The FAITH! Trial: A mHealth Intervention to Improve Cardiovascular Health Among African-Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. African American race/ethnicity~2. 18 years or older~3. Own a smart phone~4. Have basic Internet navigation skills~5. Have at least weekly Internet access (i.e. at home, church, or other public access)~6. Have an active email address~7. Intake of fruits/vegetables less than 5 servings a day~8. No engagement in regular physical activity~9. Able to engage in moderate physical activity~Exclusion criteria:~1. Unable to walk up 2 or more flights of stair or walk more than 1 city block without assistance or stopping~2. Pregnant (due to associated hormonal and weight changes)~3. Visual/hearing impairment or mental disability that would preclude independent app use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
- Delayed Intervention/Control (Type: NO_INTERVENTION): The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age 18-64~* SCID diagnosis of Schizophrenia or Schizoaffective Disorder.~* PANSS 3 factor negative symptom (screening and baseline visit 1 and visit 3) score of \>20 and PANSS total score between 60-110. Any degree of positive symptoms is acceptable but the total PANSS score must not exceed 110.~* SAS total score less than or equal to 12 and a Calgary Depression Inventory total score less than or equal to 10 and suicide (item 8) less than moderate (\<2).~* Two consecutive CGI ratings at screening and baseline (visit 1 and 3) with no change in score.~* Estimated Glomerular Filtration Rate (GFR)(a measure of renal function) greater than or equal to 60.~Exclusion criteria:~* Organic brain disorder, including epilepsy; mental retardation; or a medical condition whose pathology or treatment would likely alter the presentation or treatment of schizophrenia or significantly increase the risk associated with any of the proposed treatments~* Current DSM-IV diagnosis of drug/alcohol abuse in last month and current DSM-IV diagnosis of drug/alcohol dependence in last 6 months~* Pregnant female patients~* Impaired renal function~* Significant extrapyramidal symptoms (as reflected by a total score of 10 or above on the SAS scale), and depressive symptoms (as reflected by a score of 10 or above on the Calgary Depression Scale for Schizophrenia)~* Patients who are unable to or unwilling to participate in the Cognitive assessment (MATRICS) and the electrophysiology tasks .~* Patients on clozapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- D-serine (Type: EXPERIMENTAL): 60 mg/kg/day
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Exhibited sneezing, runny nose, and congestion for more than 9 months of the year~* Did not take medication in the previous month~* Provided written consent to enter a Chang Gung Memorial Hospital Institutional Review Board (IRB)~Exclusion Criteria:~* Sinusitis~* Nasal polyps~* unwilling or unable to complete the full course of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Herbal plaster and Acupuncture (Type: EXPERIMENTAL): In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20 years or older at obtaining informed consent~* Patients having the normal menstrual cycle (28+/-3 days) in the latest two menses before the final enrollment~* Patients having a total dysmenorrhea score of at least 3 points in two menstrual cycles before the final enrollment~Exclusion Criteria:~* Patients with ovarian chocolate cysts and symptomatic uterine fibroids (as defined in greater detail in the study protocol)~* Patients with estrogen-dependent tumors (e.g. breast cancer, cancer of the uterine body or breast fibrocystic, etc.), and patients with cervical cancer or suspected cervical cancer (e.g. class III or greater in the cervical smear or endometrial smear examination.)~* Patients with undiagnosed abnormal vaginal bleeding~* Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease(including transient ischemic attack, etc.), or coronary artery disease(e.g. myocardial infarction and angina pectoris, etc.), or a history of those diseases~* Patients aged 35 years or older who smoke at least 15 cigarettes per day~* Patients with migraine accompanied by prodrome (e.g. scintillating scotoma or star-shaped scintillation)~* Patients with pulmonary hypertension or valvular heart disease complicated by atrial fibrillation, and patients with a history of subacute bacterial endocarditis~* Patients who are regularly taking nutritional products that contain St. John's Wort~* Patients who underwent surgical treatment for endometriosis by laparotomy, or laparoscopy within 2 months prior to screening~* Patients who need to use analgesics regularly for therapeutic objectives other than relief from the pain of dysmenorrhea during this study (occasional use permitted)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DRSP 1 mg/EE 20 μg (Type: EXPERIMENTAL): 1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
- DRSP 2 mg/EE 20 μg (Type: EXPERIMENTAL): 1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
- DRSP 3 mg/EE 20 μg (Type: EXPERIMENTAL): 1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
- Placebo (Type: PLACEBO_COMPARATOR): 1 tablet per day placebo for 28 days in each 28-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Type 2 Diabetes mellitus between 18 to 65 years~* HbA1C 7% - 10%~* who can give informed consent.~* Patient uncontrolled on metformin and lifestyle modification from at least 3 months or who are metformin resistant~Exclusion Criteria:~* type 1 diabetes~* ≥1 episode of Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state,~* ≥1 episode of severe hypoglycaemia,~* Pregnant or lactating women,~* Pancreatitis,~* any serious complications or hypersensitivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Uncontrolled Diabetes with Metformin or Metformin resistant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients above 70 years of age scheduled for combined aortic valve replacement and coronary artery bypass surgery.~-~Exclusion Criteria: Patients younger than 70 years of age. Patients scheduled for other procedures than combined aortic valve replacement and coronary artery bypass surgery. Patients who are not treated with aspirin. Patients with a medical condition known to influence the hemostatic system. Patients treated with drugs other than aspirin during the last week before surgery that may influence the hemostatic system, such as warfarin (coumarin), non-steroidal antiinflammatory drugs, clopidogrel, heparin, low molecular heparins. Patients who are treated with systemic steroids. Patients with a serum creatinin concentration above 140 micromol/l. Patients with an INR above 1.5. Patients who are not able to give written informed concent.~-

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic Acid (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and Female patients with ADHD ages 18-54.~* Patient must have ADHD symptoms that cause problem(s) in the home setting.~Exclusion Criteria:~* Have failed to respond to an adequate trial of treatment with an ADHD stimulant medication, bupropion, or other nonstimulant medication.~* Are taking any antipsychotic medication or mood stabilizers within 8 weeks of Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: (abbreviated)~1. The patient has a diagnosis cervical cancer.~2. The patient understands the nature and purpose of this study and the study procedures and has signed informed consent.~3. The patient is aged \> 18 years.~4. The patient must be both chemo- and radiotherapy (RT) naïve. NB: previously low voltage RT or electron RT for non-melanoma skin cancers is allowed.~5. The patient is scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks.~6. Brachy therapy is scheduled to be initiated after the third cycle of weekly cisplatin, and preferentially after the fifth week of treatment.~7. Chemotherapy with an emetic risk potential of minimal or mild (up to 30%) is allowed on days 1-4 (see ref. 14).~8. The patient has a WHO Performance Status of ≤ 2.~Exclusion Criteria: (abbreviated)~1. The patient has a current malignant diagnosis other than cervical cancer, with exception of non-melanoma skin cancers.~2. The patient is aged \< 18 years.~3. The patient is scheduled to receive less than five weeks of fractionated radiotherapy and concomitant weekly cisplatin.~4. Brachy therapy is planned to be initiated before the third cycle of weekly cisplatin.~5. The patient has been previously treated with radiotherapy, and/or chemotherapy, with exception of treatment with low voltage RT or electron RT for non-melanoma skin cancers .~6. The patient has a WHO Performance Status of \> 2.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosaprepitant dimeglumine (Type: ACTIVE_COMPARATOR): None
- Saline water (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete